Replies to post #83147 on Innovation Pharmaceuticals Inc (IPIX)

[believer20]

So the phase two trial that was just completed and we are waiting bottom line results for will or will not satisfy the FDA for a phase three in January?

[cabel]

What is the dosing for V,...?

[daydreaming2]

Where did you come up with 2 day dosing? We have already been told the 1 day dosing is the direction B is going. As opposed to the 3 day dosing. Sometimes you really mix facts with opinions which only causes confusion, but then again almost all of your post that you try to make sound like medical facts are really just your opinion... Just the newer people don't know that! We will not go up against V, bottom line data will determine everything and you haven't seen the numbers so you are just speculating, and I would say not very well!

GLTA

[biodoc]

Jerry, sometimes I almost agree with you. Our hospital doesn't even carry daptomycin and vancomycin is used regularly. As others have posted, vancomycin is a nasty drug, dosing is somewhat complicated, and maintaining therapeutic levels is critical. I've taken the view that daptomycin is really the 'gold standard' for ABSSSI while vancomycin is the low-cost practical 'drug of choice.' I believe there are studies that show that daptomycin is actually more cost-effective than Vancomycin for bacteremia but I haven't seen any studies for ABSSSI.

It makes sense to hurdle the lowest bar to gain drug approval. For eventual marketing, most docs would be impressed with superiority to vancomycin while referencing daptomycin. However, a lot of hospitals are using a heck of a lot of daptomycin at premium pricing and those facilities aren't going to make the switch unless the argument for Brilacidin is direct and compelling.

[Yooper61]

It’s all about the cost, about the cost. Right now the overall cost per case is lower with Vanco vs. Dapto. Overall costs include drug costs, I/P, O/P, pick lines, monitoring, complications, drug interactions, resistance, readmission, etc. Dapto has a somewhat better treatment regimen, dosing once per day vs. possibly twice for Vanco, and 7 – 14 days vs. 14 days. Any savings in non-drug costs do not outweigh the drug cost of Dapto. Thus, Dapto is only used when Vanco cannot be used. However, when Dapto goes generic, it will displace Vanco as the drug of choice, IMO(beating out Sivextro and Dalvance). So the question is…how will Bril compete with a generic Dapto? I believe Bril will be the drug of choice over a generic Dapto because the reasons you post will generate non-drug cost savings that will exceed the cost of Bril. I am waiting for the bottom line data to post further detail on this view.

[stevo99]

B can take on V or D with ease if the one day treatment holds...

Came across this article:

http://www.biocentury.com/biotech-pharma-news/coverstory/2011-08-01/optimer-cubist-hoping-for-first-line-market-for-antibiotic-dificid-in-cdad-a1

"Initially, we had to communicate with doctors about the rapid bactericidal effects of Cubicin vs. IV vancomycin," Perez said.

Phase III results in 562 patients with cSSTIs showed only 21% of Cubicin patients required >7 days of treatment vs. 60% for the comparator group receiving either vancomycin or a semi-synthetic penicillin; 79% of those receiving once-daily Cubicin required 4-7 days of IV treatment vs. 40% of patients.